CoChat

Long-term Tumor Regression Induced by an Antibody–Drug Conjugate That Targets 5T4, an Oncofetal Antigen Expressed on Tumor-Initiating Cells

Sapra, Puja, Damelin, Marc, DiJoseph, John, Marquette, Kimberly, Geles, Kenneth G., Golas, Jonathon, Dougher, Maureen, Narayanan, Bitha, Giannakou, Andreas, Khandke, Kiran, Dushin, Russell, Ernstoff, Elana, Lucas, Judy, Leal, Mauricio, Hu, George, O'Donnell, Christopher J., Tchistiakova, Lioudmila, Abraham, Robert T., Gerber, Hans-Peter · 2013 · Molecular Cancer Therapeutics
Cited by 80

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Antibody–drug conjugates (ADC) represent a promising therapeutic modality for the clinical management of cancer. We sought to develop a novel ADC that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells (TIC), which comprise the most aggressive cell population in the tumor. We optimized an anti-5T4 ADC (A1mcMMAF) by sulfydryl-based conjugation of the humanized A1 antibody to the tubulin inhibitor monomethylauristatin F (MMAF) via a maleimidocaproyl linker. A1mcMMAF exhibited potent in vivo antitumor activity in a variety of tumor models and induced long-term regressions for up to 100 days after the last dose. Strikingly, animals showed pathologic complete response in each model with doses as low as 3 mg antibody/kg dosed every 4 days. In a non–small cell lung cancer patient-derived xenograft model, in which 5T4 is preferentially expressed on the less differentiated tumor cells, A1mcMMAF treatment resulted in sustained tumor regressions and reduced TIC frequency. These results highlight the potential of ADCs that target the most aggressive cell populations within tumors, such as TICs. In exploratory safety studies, A1mcMMAF exhibited no overt toxicities when administered to cynomolgus monkeys at doses up to 10 mg antibody/kg/cycle × 2 and displayed a half-life of 5 days. The preclinical efficacy and safety data established a promising therapeutic index that supports clinical testing of A1mcMMAF. Mol Cancer Ther; 12(1); 38–47. ©2012 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-12-0603

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Drug penetration in solid tumours

    Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805 · cited 1×

    “Cells cultured in the presence of an extracellular matrix grow as 3-dimensionalmulticellular spheroids in amicroenvironment that mimics native tumor tissue and can responddifferently to drugs comparedwith cells cultured inmonolayer cultures (22).”
    Background

Show all 1 references

Cited by

See all 80

Metadata

Authors
Sapra, P., Damelin, M., DiJoseph, J., Marquette, K., Geles, K. G., Golas, J., Dougher, M., Narayanan, B., Giannakou, A., Khandke, K., Dushin, R., Ernstoff, E., Lucas, J., Leal, M., Hu, G., O'Donnell, C. J., Tchistiakova, L., Abraham, R. T., & Gerber, H.-P.
Venue
Molecular Cancer Therapeutics
Published
2013-01-01
Volume
12
Issue
1
Pages
38-47
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2104998312
Cited by
80
References
1
FWCI
6.23
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term Tumor Regression Induced by an Antibody–Drug Conjugate That Targets 5T4, an Oncofetal Antigen Expressed on Tumor-Initiating Cells. https://app.cochat.ai/papers/10.1158/1535-7163.mct-12-0603
The paper
Sapra, P., Damelin, M., DiJoseph, J., Marquette, K., Geles, K. G., Golas, J., Dougher, M., Narayanan, B., Giannakou, A., Khandke, K., Dushin, R., Ernstoff, E., Lucas, J., Leal, M., Hu, G., O'Donnell, C. J., Tchistiakova, L., Abraham, R. T., & Gerber, H.-P. (2013). Long-term Tumor Regression Induced by an Antibody–Drug Conjugate That Targets 5T4, an Oncofetal Antigen Expressed on Tumor-Initiating Cells. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-12-0603

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.